Aflibercept (VEGF Trap-Eye) differs from ranibizumab in that it:

• A Binds exclusively to VEGF-A and cannot neutralize placental growth factor (PlGF)
• B Has a shorter intravitreal half-life requiring monthly injections compared to ranibizumab's 3-monthly schedule
• C Is administered subconjunctivally for macular degeneration
• D Is a fusion protein that binds VEGF-A, VEGF-B, and PlGF with higher affinity than ranibizumab ✓

Explanation

Aflibercept is a recombinant fusion protein combining domains from VEGFR-1 and VEGFR-2 fused to the Fc portion of IgG1. It binds VEGF-A (all isoforms), VEGF-B, and PlGF with higher binding affinity than ranibizumab or bevacizumab, providing a broader anti-angiogenic effect and a longer intravitreal half-life (~9 days vs ~9 days for ranibizumab, but higher binding affinity allows 8-week dosing intervals). Both are intravitreal injections.

Reference: Khurana Comprehensive Ophthalmology, 7th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.